NSG 520 Unit 6 Lab Value Interpretation Table Example

Course	NSG 520 Pathophysiology and Pharmacology
Unit	Unit 6
Paper type	Abnormal value interpretation table
Length	About 550 words, 4 pages
Format	APA 7 student paper
School	Herzing University
Program	MSN
Updated	October 2026

Free sample paper for NSG 520 Unit 6

Reading Mrs. D.'s Laboratory Panel Mechanistically: Eleven Values in Stage 3b Diabetic Kidney Disease, What Each Reflects, and What a Move in Either Direction Would Mean

Student Name

Department of Nursing, Herzing University

NSG 520: Pathophysiology and Pharmacology

Instructor Name

February 25, 2026

What this page is doingThe title promises the mechanism behind each value and what its movement would mean. A table that only flags values as high or low tells a reader what to notice, but not what is happening in the body or what to do.

Reading Mrs. D.'s Laboratory Panel Mechanistically: Eleven Values in Stage 3b Diabetic Kidney Disease, What Each Reflects, and What a Move in Either Direction Would Mean

The Record

The patient, Mrs. D., is a composite 68-year-old whose diabetes has affected her kidneys; she takes metformin 500 mg twice daily, glipizide 2.5 mg daily, dapagliflozin 10 mg daily, lisinopril 20 mg daily, and, for the past month, finerenone 10 mg daily. The panel below was drawn at her four-week check after starting finerenone. Values are described by their usual direction in general terms rather than against a particular laboratory's reference range, since ranges differ between laboratories.

The Table

Each row states the value, the process that produces it, what a rise or fall would mean, and its bearing on her drugs.

Parameter, value	Process producing it	If it rose	If it fell	Bearing on her drugs
Glycated hemoglobin, 7.4%	Glucose binding to hemoglobin over the red cell's life	Worse average glucose over about three months	Better control; can be falsely low if red cell life is short, as in anemia or blood loss	Anemia may make it read lower than her true glucose average
Serum creatinine, 1.5 mg/dL; estimated filtration rate 35	Creatinine from muscle, cleared by filtration	Falling filtration; if abrupt, consider dehydration or drug effect	Improving filtration or less muscle mass	Guides metformin, finerenone, and dapagliflozin decisions
Urine albumin-to-creatinine ratio, 290 mg/g	Albumin crossing a damaged filtration barrier	Progressing glomerular injury	Response to treatment	Target of all three kidney-protective drugs
Potassium, 5.1 mmol/L	Balance of intake, cell shifts, and excretion in the collecting duct	Reduced excretion, from less aldosterone effect or falling filtration	Diuretic effect, poor intake	Lisinopril and finerenone both raise it; dapagliflozin may lower it
Bicarbonate, 21 mmol/L	Kidney acid excretion and bicarbonate regeneration	Resolution of acidosis or vomiting	Worsening metabolic acidosis of kidney disease	Metformin accumulation would lower it further
Hemoglobin, 10.9 g/dL	Red cell production, driven by erythropoietin from kidney cells	Recovery of production	Less erythropoietin, iron deficiency, or bleeding	Affects glycated hemoglobin interpretation
Phosphate, 4.7 mg/dL	Intake and kidney excretion	Reduced excretion as filtration falls	Low intake, refeeding, excess binders	Diet and binders if it keeps rising
Parathyroid hormone, 118 pg/mL	Parathyroid response to phosphate, calcium, and vitamin D	Secondary hyperparathyroidism progressing	Treatment response or oversuppression	Links to phosphate and vitamin D
25-hydroxyvitamin D, 22 ng/mL	Stores from skin and diet	Replacement working	Low stores, common in kidney disease	Replace if low, a step toward controlling hormone levels
Urea nitrogen, 34 mg/dL	Protein breakdown, cleared by filtration and affected by volume	Falling filtration, dehydration, high protein intake, bleeding	Low protein intake, liver disease	A rise with dapagliflozin started may reflect volume loss
LDL cholesterol, 92 mg/dL	Hepatic production and clearance	Higher cardiovascular risk	Treatment effect	Kidney disease raises cardiovascular risk; statin intensity reviewed

Reading the Values Together

Three clusters emerge. The first is the kidney-protection cluster: creatinine and filtration rate have been stable since the expected small dip when dapagliflozin was started, and albuminuria has fallen from 420 to 310 to 290 mg/g over the course of her treatment, suggesting that the three drugs are working together. The second is the potassium cluster: a rise from 4.8 to 5.1 mmol/L after starting finerenone is the predicted effect of blocking the mineralocorticoid receptor in the collecting duct, on top of the aldosterone reduction from lisinopril. It does not require stopping finerenone at this level, but it rules out increasing the dose now and calls for a diet review and a recheck in four weeks.

The third cluster is the chronic kidney disease complications that are easy to overlook while attention is on glucose and albumin: mild anemia, a low bicarbonate, and the beginning of mineral and bone disorder with a rising parathyroid hormone and low vitamin D. Anemia in kidney disease arises mainly from reduced erythropoietin production by the kidney, with iron deficiency and inflammation contributing (Babitt & Lin, 2012), so iron studies should be checked before anything else. Rising parathyroid hormone and low vitamin D are managed according to the kidney mineral and bone guideline, which recommends addressing vitamin D deficiency and phosphate first rather than treating the hormone level alone (Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group, 2017).

What this page is doingThe values are read together, in clusters that share a mechanism. Interpreting each value in isolation would miss that the potassium rise was predicted by a drug started a month earlier, and that the anemia affects how the glycated hemoglobin should be read.

One Value That Can Mislead

The glycated hemoglobin of 7.4% deserves caution. Because it depends on how long red cells circulate, anemia of kidney disease, blood loss, or iron replacement can make it read lower or change faster than true glucose control. If her hemoglobin falls further or she starts iron or an erythropoiesis-stimulating agent, a glucose meter record or a continuous glucose monitor would give a more reliable picture than the glycated hemoglobin alone.

Actions From the Panel

Keep finerenone at 10 mg; recheck potassium and kidney function in four weeks; review potassium in diet and salt substitutes. Order iron studies and a reticulocyte count for the anemia. Start vitamin D replacement and review phosphate intake with a dietitian. Recheck bicarbonate; if it falls below 18 mmol/L, consider alkali therapy and reassess metformin. Review statin therapy given her cardiovascular risk. Each action follows from a mechanism in the table rather than from a value flagged as abnormal, consistent with the guideline's emphasis on managing the whole picture of diabetes in kidney disease rather than glucose alone (Rossing et al., 2022).

References

Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 23(10), 1631-1634. https://doi.org/10.1681/ASN.2011111078

Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International Supplements, 7(1), 1-59. https://doi.org/10.1016/j.kisu.2017.04.001

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., & de Boer, I. H. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008

The Herzing NSG 520 Unit 6 instructions

Unit 6 asks you to interpret a patient's lab panel by the mechanism behind each value. Expect to describe the patient and medications, build a table with each value, its producing process, the meaning of change and its bearing on treatment, group values into clusters, flag values that may mislead and list actions. Students often ask how many values to include and how to show mechanism. Ten to twelve values give a full picture. Mechanism means what process produces the value, such as erythropoietin and hemoglobin. Clusters show how values relate. Some values, such as A1C in kidney disease, can mislead, and naming that shows depth. Actions should follow from the panel.

How this NSG 520 Unit 6 example is built

The table opens with the patient's diagnoses and current drugs. Eleven rows each give the value, the process behind it, what a change would mean and its bearing on her drugs, such as potassium and finerenone. The cluster section groups values into kidney, electrolyte and anemia-bone sets and explains how each set moves together. The misleading value section explains why A1C may read low in kidney disease and suggests alternatives, such as fructosamine or continuous glucose monitoring. The action section lists specific steps with dates, from rechecking potassium to reviewing anemia. Each interpretation ties back to a mechanism, so the panel reads as an explanation of her body rather than a list of flags.

Reading the NSG 520 Unit 6 rubric

Herzing's rubric for a lab interpretation table usually covers patient context, mechanism for each value, meaning of change, bearing on treatment, clustering, misleading values and actions. Mechanism and bearing on treatment carry the most weight, because the course links lab science to prescribing decisions. Context points reward diagnoses and the current medication list. Mechanism criteria look for the process that produces each value, not just its normal range. Clustering earns credit when related values are read together. Misleading value points go to known limits, such as A1C in kidney disease. Action criteria reward specific steps with dates and thresholds. Consistent units are expected. KDIGO guidance and Bloomgarden's discussion of A1C limits support the interpretation.

NSG 520 Unit 6 help: mistakes that cost points

Lab tables in Unit 6 commonly lose points by labeling values high or low without explaining the process behind them. Another frequent problem is ignoring how each value bears on the patient's drugs. Students often read values one by one without clustering. A1C is taken at face value in kidney disease. Actions are missing or vague, such as monitor labs. Units are inconsistent. The patient's medications are not listed. Trends from earlier panels are not used, though one value means little alone. Anemia and bone values are skipped as unrelated. Finally, explain what produces each value, because graders reward a table that turns numbers into mechanisms and mechanisms into decisions.

Get a NSG 520 Unit 6 example written to your instructions

Send the Unit 6 instructions and the rubric from your NSG 520 classroom, with the values and the case your course provides. We write a custom example that groups rows by process, keeps a fixed order inside each one, reads every value in both directions and adds the pharmacological bearing. First custom sample free, returned in 24 to 48 hours.

More NSG 520 papers and MSN samples

NSG 520 Unit 6 questions, answered

Should the table include reference ranges?

Include them only if your instructions ask, and then take them from the laboratory or reference your course names rather than from memory, since ranges differ between laboratories and by method. The reasoning the criteria reward is what a movement means, not the boundary itself, so the explanation columns are where the effort belongs in this deliverable.

How many values belong in the table?

Enough to cover the systems the case involves, grouped so the connections are visible. A long table of unrelated parameters with one line each reads as transcription, while a shorter one with real interpretation and grouped commentary shows the understanding the criteria look for. Follow any count the instructions give and spend the room on the explanation columns.

Does every value need a drug connection?

Not every one, but the column should be filled wherever a connection genuinely exists and left honest where it does not. Forcing a pharmacological link onto a value that has none is more visible than leaving a cell marked as not applicable. Where a value does bear on handling, say which step and treat the specifics as something verified.

Where can I find a free NSG 520 Unit 6 sample paper?

Read the complete NSG 520 Unit 6 lab interpretation table here at no charge, eleven values read by mechanism with actions. Ask for a custom table on your own patient's panel.

Is hemoglobin A1C accurate in chronic kidney disease?

It can underestimate glucose because red blood cells live shorter lives in kidney disease and anemia. This sample flags Mrs. D.'s A1C of 7.4 percent for that reason and suggests other ways to track glucose.

NSG 520 Unit 6 abnormal value interpretation table example